Strykagen Business Model
- Dedicated to developing therapies, diagnostics and biomarkers for muscular dystrophy
- Development of life changing therapeutics for rare muscle diseases
- Established scientific team with expertise in muscular dystrophy translational research
- Partnerships with academic institutions
- Relationships with patient advocacy groups
Strykagen Pipeline
- Exclusive market for products through orphan drug status
- Robust product pipeline for the muscular dystrophies
- Prolonged product lifespan for rare muscle diseases
- Extended product application for aging, cachexia and sports injuries